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Variables Overall 2003 2009 P
Surgical outcomes
Return to OR 14% 16% 7% .0001
Blood transfusion 2 U 5% 8% 3% .041
Wound infection 5% 5% 3% .026
1-year amputation-free survival 94/79% 94/81% 92/78%a NS
1-year graft patency (claudication/
CLI)
91/84% 89/85% 95/90%a NS
1-year limb salvage (claudication/
CLI)
98/89% 99/89% 94/88%a NS
aValues used from 2008 to allow for capture of 1-year outcomes.
Outcomes Following Endovascular Intervention for Chronic Critical
Limb Ischemia by Rutherford Classification
Maciej L. Dryjski, MD, PhD, Monica O’Brien-Irr, MS, RN, Linda Harris,
MD, and Hasan Dosluoglu, MD, Kaleida Health, Buffalo, NY
Objective: This study evaluated outcomes after endovascular interven-
tion (EVI) for chronic critical limb ischemia (CLI) by Rutherford class
(RC4: rest pain; RC5: tissue loss).
Methods: The medical records of all EVI performed for RC 4-5 by
vascular surgeons at a single institution during a 3-year period were
reviewed for the following outcomes. Sustained clinical success (SCS)—
Rutherford Improvement Score (RIS): 2, without target extremity
revascularization (TER). In RC5 patients, patency until healing; healing
4 months without recurrence or new ulceration. Secondary sustained
clinical success (SSCS)—RIS: 2 with TER. In RC5 patients; patency
until healing; healing at any time during follow-up, without recurrent or
new ulceration. Data were analyzed using SPSS. Significance was estab-
lished at the 0.05 level.
Results: Of 106 EVI performed, 78 (74%) were RC5. There were 39
men (37%). Mean age was 73 12. Mean follow-up was 19 months (range,
1-44). Table I: Significant differences between RC4 and RC5 were found.
Outcomes were significantly better for RC-4. Table II: Independent predic-
tors of failure of SCS and SSCS in RC5 are shown: Table III. SSCS in RC5
patients with DM and CHF was 11%, 33% when either CHF or DM were
present and 72% when neither were present (P  .009).
Conclusions:Outcome after EVI for RC4 was significantly better than
for RC5, favoring early intervention. Limb salvage was acceptable in RC5
yet, SCS (early wound healing without TER) occurred in only 21%. Diabetes
and CHF were predictors of poor SSCS. Careful selection of patients may
improve outcome in RC5.
Table I.
RC Distal EVI DM Dialysis Current smoker
RC4 29% 32% 0% 57%
RC5 53% 58% 14% 32%
P .029 .020 .036 .023
Table II.
RC 24-mon survival 24-mon limb salvage SCS SSCS
RC4 84%  8% 100% 48% 85%
RC5 62%  7% 83%  4% 21% 39%
P .09 .026 .006 .001
Table III.
Outcome
Independent
predictor Odds ratio
Confidence
interval P
SCS DM 3.76 1.04—13.69 .04
SSCS DM 4.69 1.42—15.63 .011
SSCS CHF 4.07 0.99—16.67 .05Lesion and Device Characteristics That Predict Distal Embolization
During Percutaneous Lower Extremity Interventions
Gautam V. Shrikhande, MD,HafizHussain, MD, Sikander Khan,MD, Rajeev
Dayal, MD, Katherine Gallagher, MD, James F. Mckinsey, MD, and Nicholas
Morrissey, MD, Columbia University Medical Center, New York, NY
Objectives: Distal embolization (DE) during percutaneous lower ex-
tremity revascularization (LER)may cause severe clinical sequelae. To better
define DE, we investigated which lesion characteristics and treatment mo-
dalities increase the risk for embolization.
Methods: A prospective registry of LER from 2004-2009 was re-
viewed. All cases with runoff evaluated before and after intervention were
included. Angiograms and operative reports were reviewed for evidence of
DE. Rates of DE were analyzed with 2, and outcomes were analyzed by
log-rank analysis. The study included 2137 lesions.
Results: Tables I and II report DE rates for lesions/modalities. DE
rate was unchanged by runoff status and did not affect limb salvage. In 32 of
34 cases of DE, patency was restored before leaving the OR.
Conclusions: DE is a rare event that occurs more often with CSI and
Pathway devices. In-stent and complex native lesions are at higher risk for
DE. DE has no effect on limb salvage and is typically reversible with
endovascular techniques.
Scientific Session VI
Simultaneous TEVAR and EVAR is Feasible with Minimal Morbidity
and Mortality
Melissa L. Kirkwood, MD, Alberto Pochettino, MD, Ronald M. Fairman,
MD, Benjamin M. Jackson, MD, Joseph E. Bavaria, MD, and Edward Y.
Woo, MD, Hospital of the University of Pennsylvania, Philadelphia, Pa
Objective: To determine the results of simultaneous TEVAR and
EVAR.
Methods: Records were retrospectively reviewed. Seven patients (5
men; mean age, 73 years) underwent simultaneous TEVAR and EVAR
between 1999-2009 at a single center. All patients had concomitant thoracic
and abdominal aneurysms. The average diameters of the thoracic and
abdominal aneurysms were 6.6 and 6.3 cm, respectively. Three patients were
treated emergently, and the remainder had urgent indications for simulta-
neous repair. All patients had significant comorbidities (HTN, CAD, CHF,
smoking, COPD).
Results: Average procedural time was 165 minutes. Spinal drainage
and neuromonitoring was used in all cases. TEVAR was performed before
Table I. Incidence of distal embolization based on
treatment modality
Intervention Lesions Distal embolization
No. No. (%)
PTA 570 5 (0.87)
PTA  stent 740 5 (0.67)
Silverhawk ATH 736 14 (1.9)
Newer ATH devices (Pathway, CSI) 36 8 (22.2)a
Laser 55 2 (3.63)
Total 2137 34 (1.59)
aIndicates P  .05 compared with PTA.
Table II. Embolization by lesion type and TASC
Variable Lesions Distal embolization
No. No. (%)
Lesion type
Stenosis 1334 13 (0.97)
Occlusion 615 15 (2.4)a
In-stent stenosis 188 6 (3.19)a
Total 2137 34 (1.59)
TASC
A/B 929 8 (0.86)
C/D 1208 26 (2.15)a
Total 2137 34 (1.59)
aDenotes statistical significance (P  .05).EVAR. Access was through the common femoral arteries in five patients.
Two patients required direct cannulation of the iliac artery for delivery of the
